Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the USA / NCT05919511
Recruiting Observational

Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease

NCT05919511 · tracked via the Priya Life Science USA tracker
Sponsor
Incyte Corporation
Phase
Observational
Started
2023-08-01
Last updated
2026-10-06

Condition(s) studied

cGVHD

Investigational drug(s) / intervention(s)

Non-Interventional

Non-Interventional: This is an observational study

Study summary

The purpose of this prospective observational study is to collect data from participants who have recently had an allogenic Stem Cell Transplant(alloSCT) and are at risk of Chronic Graft Versus Host Disease(cGVHD)

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age ≥ 18 years inclusive at the time of signing the ICF * Allogeneic SCT 90 to 180 days prior to enrollment * Able to comprehend and willing to provide informed consent * Willing and able to complete participant-assessment questionnaires either alone or with minimal assistance from a caregiver and/or trained site personnel Exclusion Criteria: * There are no exclusion criteria for this study

Primary outcome measure(s)

  • Overall Burden of cGVHD diagnosis and severity — 36 months

Trial sites (37)

FacilityCityRegionStatus
University of Alabama Birmingham Birmingham Alabama Recruiting
Mayo Clinic Arizona Phoenix Arizona Recruiting
City of Hope Duarte California Recruiting
USC Norris Comprehensive Cancer Center Los Angeles California Recruiting
University of Colorado Aurora Colorado Recruiting
Colorado Blood Cancer Institute/Presbyterian St. Luke's Denver Colorado Recruiting
Mayo Clinic Jacksonville Jacksonville Florida Recruiting
AdventHealth Orlando Orlando Florida Recruiting
Moffit Cancer Center Orlando Florida Recruiting
Emory University Atlanta Georgia Recruiting
Georgia Cancer Center Augusta Georgia Recruiting
Northwestern University Chicago Illinois Recruiting
Rush University Medical Group Chicago Illinois Recruiting
The University of Chicago Chicago Illinois Recruiting
Loyola University Medical Center Maywood Illinois Recruiting
The University of Kansas Clinical Research Center Fairway Kansas Recruiting
Tulane Cancer Center New Orleans Louisiana Completed
University of Maryland Medical Center Baltimore Maryland Recruiting
Massachusetts Cancer Research Center Boston Massachusetts Recruiting
Karmanos Cancer Institute Detroit Michigan Recruiting
Corewell Health Grand Rapids Michigan Recruiting
Mayo Clinic Rochester Rochester Minnesota Recruiting
Rutgers Cancer Institute of New Jersey New Brunswick New Jersey Recruiting
Memorial Sloan Kettering Cancer Center New York New York Recruiting
University of North Carolina at Chapel Hill Chapel Hill North Carolina Recruiting
Levine Cancer Institute Charlotte North Carolina Recruiting
The Ohio State University Columbus Ohio Recruiting
Oregon Health Sciences University Portland Oregon Recruiting
Geisinger Health Systems Danville Pennsylvania Recruiting
Tristar Centennial Blood & Marrow Transplant Nashville Tennessee Recruiting
Vanderbilt University Medical Center Nashville Tennessee Recruiting
Sarah Cannon Blood Cancer Center at St. Davids's South Austin Medical Center Austin Texas Recruiting
Texas Oncology-Baylor Charles A. Sammons Cancer Center Dallas Texas Recruiting
Methodist Hospital San Antonio Texas Recruiting
University of Utah, Huntsman Cancer Institute Salt Lake City Utah Recruiting
Fred Hutchinson Cancer Research Center Seattle Washington Recruiting
Medical College of Wisconsin Milwaukee Wisconsin Recruiting

More Incyte Corporation trials in the USA

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo Recruiting
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer Recruiting
A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms Active, not recruiting
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05919511 on ClinicalTrials.gov ↗ ← All trials in the USA